{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:50:31Z","timestamp":1791928231580,"version":"4.3.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009096","name":"Taiwan Clinical Oncology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Taxanes-containing chemotherapy constitutes an essential backbone for both early and metastatic breast cancer (mBC). However, the two major taxane drugs\u2014paclitaxel and docetaxel\u2014have distinct safety profiles. In this review, we summarize the safety outcome and management following treatment with both taxanes from selected clinical trials. We utilized PubMed to perform literature search before April 2021. Five phase III randomized controlled trials with reports of individual taxane adverse events (AEs) were included in this review. Grade 3\/4 AEs were summarized and discussed extensively. The rates of grade 3\/4 neutropenia were higher with docetaxel than with paclitaxel. For non-hematologic grade 3\/4 AEs, peripheral neuropathy was more frequent with paclitaxel while fluid retention was more frequent with docetaxel. Compared to paclitaxel, docetaxel had a higher rate of grade 3\/4 gastrointestinal AEs. Grade 3\/4 myalgia were generally comparable between the two taxanes. Except for neutropenia, the incidence rate of grade 3\/4 AEs of taxanes was generally manageable. Peripheral neuropathy was more common with paclitaxel while grade 3\/4 neutropenia was more common with docetaxel.<\/jats:p>","DOI":"10.3389\/fonc.2022.940239","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T08:16:44Z","timestamp":1665476204000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["A systemic review of taxanes and their side effects in metastatic breast cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Jiun-I.","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Chung","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ming","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/jco.2007.11.3787","article-title":"Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials","volume":"26","author":"De Laurentiis","year":"2008","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"Cd004421","DOI":"10.1002\/14651858.CD004421.pub2","article-title":"Taxanes for adjuvant treatment of early breast cancer","author":"Ferguson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2016.17.s3.43","article-title":"Incidence and mortality and epidemiology of breast cancer in the world","volume":"17","author":"Ghoncheh","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.5.609","article-title":"Paclitaxel: A review of adverse toxicities and novel delivery strategies","volume":"6","author":"Marupudi","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.02.027","article-title":"Randomized phase iii study of docetaxel compared with paclitaxel in metastatic breast cancer","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"B6","unstructured":"CompanyB-MS\n          Taxol\u00ae (Paclitaxel) injection2011"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.02.063","article-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909638","article-title":"Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer","volume":"362","author":"Swain","year":"2010","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1995.13.10.2575","article-title":"Phase ii trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer","volume":"13","author":"Seidman","year":"1995","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2001.19.22.4216","article-title":"Multicenter phase ii trial of weekly paclitaxel in women with metastatic breast cancer","volume":"19","author":"Perez","year":"2001","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in Her2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz061","article-title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for Her2-positive locally recurrent or metastatic breast cancer (Peruse)","volume":"30","author":"Bachelot","year":"2019","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh131","article-title":"Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer","volume":"96","author":"Pegram","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6353","article-title":"Taxanes enhance trastuzumab-mediated adcc on tumor cells through Nkg2d-mediated nk cell recognition","volume":"7","author":"Di Modica","year":"2016","journal-title":"Oncotarget"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/tbj.14123","article-title":"Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer","volume":"26","author":"Pabst","year":"2020","journal-title":"Breast J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(00)00134-9","article-title":"Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: Quality of life evaluation using the eortc qlq-C30 and the Rotterdam symptom checklist","volume":"36","author":"Kramer","year":"2000","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9651-3","article-title":"A phase-iii trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: Results of the erasme 3 study","volume":"109","author":"Cassier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1997.15.9.3149","article-title":"Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European organization for research and treatment of cancer investigational drug branch for breast cancer","volume":"15","author":"Piccart","year":"1997","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2011.09.016","article-title":"Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-El, tween-80 and tween-20","volume":"45","author":"Weiszh\u00e1r","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211409473","article-title":"Dexamethasone premedication for prophylaxis of taxane toxicities: Can the doses be reduced when paclitaxel or docetaxel are given weekly","volume":"18","author":"Schwartz","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.36.2079","article-title":"Phase iii trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.48.1275","article-title":"Definitive results of a phase iii adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: The nsabp b-38 trial","volume":"31","author":"Swain","year":"2013","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30421","article-title":"Comparison of an Ac-taxane versus Ac-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the national surgical adjuvant study of breast cancer 02 trial, a randomized comparative phase 3 study","volume":"123","author":"Watanabe","year":"2017","journal-title":"Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.bjc.6602000","article-title":"A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer","volume":"91","author":"Harries","year":"2004","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/JTO.0b013e318161225e","article-title":"Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: Cancer and leukemia group b study 39901","volume":"3","author":"Graziano","year":"2008","journal-title":"J Thorac Oncol"},{"key":"B26","article-title":"Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer","volume":"32","author":"Tamiya","year":"2012","journal-title":"Anticancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","article-title":"Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group b protocol 9840","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3088-3","article-title":"Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study Brenda ii","volume":"24","author":"Schwentner","year":"2016","journal-title":"Support Care Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000320640","article-title":"Prospective multicenter randomized phase iii study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer","volume":"79","author":"Stemmler","year":"2010","journal-title":"Oncology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.12.018","article-title":"Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel","volume":"47","author":"Schr\u00f6der","year":"2011","journal-title":"Eur J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/cancers11040564","article-title":"Tumor-associated neutrophils in cancer: Going pro","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1487-6","article-title":"Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy","volume":"68","author":"Shitara","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0909-3","article-title":"Chemotherapy-induced neutropenia as a prognostic and predictive marker of outcomes in solid-tumor patients","volume":"78","author":"Kasi","year":"2018","journal-title":"Drugs"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16980","article-title":"Timing of chemotherapy-induced neutropenia: The prognostic factor in advanced pancreatic cancer patients treated with gemcitabine \/ gemcitabine-based chemotherapy","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S40601","article-title":"Presentation and management of docetaxel-related adverse effects in patients with breast cancer","volume":"6","author":"Ho","year":"2014","journal-title":"Cancer Manag Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl135","article-title":"Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (Tac) or 5-fluorouracil, doxorubicin and cyclophosphamide (Fac): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the tac regimen","volume":"17","author":"Mart\u00edn","year":"2006","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.06.4451","article-title":"2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2015.12.009","article-title":"Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (Mcrpc): A Post-hoc analysis of the tropic phase iii trial","volume":"56","author":"Meisel","year":"2016","journal-title":"Eur J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.4_suppl_1.152s","article-title":"Paclitaxel in advanced non-small cell lung cancer : An alternative high-dose weekly schedule","volume":"117","author":"Akerley","year":"2000","journal-title":"Chest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23321","article-title":"Phase 3 study comparing the use of docetaxel on an every-3-Week versus weekly schedule in the treatment of metastatic breast cancer","volume":"112","author":"Rivera","year":"2008","journal-title":"Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00c3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00613.x","article-title":"The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication","volume":"43","author":"B\u00e9har","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1998.16.10.3426","article-title":"Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment","volume":"16","author":"Semb","year":"1998","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2547-y","article-title":"Awareness of the adverse effects associated with prophylactic corticosteroid use during docetaxel therapy","volume":"23","author":"Yoo","year":"2015","journal-title":"Support Care Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210367950","article-title":"Single premedication dose of dexamethasone 20 mg iv before docetaxel administration","volume":"17","author":"Chouhan","year":"2011","journal-title":"J Oncol Pharm Pract"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2011.09.003","article-title":"Intravenous therapies for castration-resistant prostate cancer: Toxicities and adverse events","volume":"30","author":"Singer","year":"2012","journal-title":"Urol Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2013.1264","article-title":"Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation","volume":"7","author":"Wang","year":"2013","journal-title":"Mol Med Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2000.18.1.102","article-title":"Paclitaxel-associated hypersensitivity reactions: Experience of the gynecologic oncology program of the Cleveland clinic cancer center","volume":"18","author":"Markman","year":"2000","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008207025430","article-title":"Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions","volume":"8","author":"Bookman","year":"1997","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3109\/1547691X.2012.708365","article-title":"Cimetidine enhances delayed-type hypersensitivity responses and serum interleukin (IL)-2, -10, -12, and IL-17 levels after burn injury in an animal model","volume":"10","author":"Jafarzadeh 1","year":"2013","journal-title":"J Immunotoxicol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(12)70537-5","article-title":"2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: A randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70018-x","article-title":"Management of prostate cancer in older patients: Updated recommendations of a working group of the international society of geriatric oncology","volume":"15","author":"Droz","year":"2014","journal-title":"Lancet Oncol"},{"key":"B55","article-title":"Polychemotherapy for early breast cancer: An overview of the randomised trials. early breast cancer trialists' collaborative group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase iii trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.11.9362","article-title":"Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment","volume":"26","author":"Albain","year":"2008","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32175","article-title":"Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice","volume":"125","author":"Nyrop","year":"2019","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.940239\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T08:16:50Z","timestamp":1665476210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.940239\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":58,"alternative-id":["10.3389\/fonc.2022.940239"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.940239","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"article-number":"940239"}}